Results 171 to 180 of about 2,568,476 (309)

Sex Differences in Patient-Reported Outcomes Among People Living With HIV Switching to an Oral Dual Therapy: Results From the PROBI Study

AIDS Research and Treatment
Tristan Alain, Fabienne Marcellin, Pascal Bessonneau, Laurent Hocqueloux, Holger Muehlan, Clotilde Allavena, David Zucman, Ester Villalonga-Olives, Olivier Chassany, Martin Duracinsky   +9 more
doaj   +1 more source

Feasibility of patient-reported outcomes collection in clinical routine at a radiotherapy department. [PDF]

Acta Oncol
Fagerström Kristensen I, Linnér A, Nilsson M, Rogowski V, Munck Af Rosenschöld P, Jerkeman M.   +5 more
europepmc   +1 more source

Interaction of HS1BP3 with cortactin modulates TKS5 localisation, cell secretion and cancer malignancy

Molecular Oncology, EarlyView.
Here, we demonstrate that HS1BP3 interacts with Cortactin through a proline‐rich region (PRR3.1) and show that this interaction, and HS1BP3 itself, promote cancer cell proliferation and invasion. Inhibition of this interaction leads to build‐up of TKS5 in multivesicular endosomes and altered secretion of CD63 and CD9, providing an explanation for the ...
Arja Arnesen Løchen, Kristiane Søreng, Chiara Veroni, Laura Trachsel‐Moncho, Nagham Asp, Robin Gaupset, Lars Gustav Lyckander, Helene Knævelsrud, Lars Eftang, Anne Simonsen   +9 more
wiley   +1 more source

Patient-Reported Outcomes (PROs): because good questions outrank easy answers.

, 2009
Patient-Reported Outcomes (PROs): because good questions outrank easy ...
J Speight (7755977)
core  

A 360 Degree Qualitative Ethical Assessment of Reporting Patient Reported Outcomes. [PDF]

J Empir Res Hum Res Ethics
Huang AP, Corcoran J, Zizzi C, DeFehr C, Contento A, Ross L, Kluger B.   +6 more
europepmc   +1 more source

ESR1 methylation and ESR1 mutations in circulating tumor cells (CTCs) and paired plasma‐cfDNA of advanced breast cancer patients: A feasibility proof‐of‐concept study

Molecular Oncology, EarlyView.
Circulating tumor cells (CTCs) and plasma cell‐free DNA (cfDNA) were analyzed to detect ESR1 mutations and methylation in patients with advanced breast cancer. CTC‐derived DNA showed higher sensitivity for mutation detection and revealed complementary genetic and epigenetic alterations, highlighting the added value of CTC analysis for understanding ...
Dimitra Stergiopoulou, Athina Markou, Eleonora Nicolo, Mara S Serafini, Qiang Zhang, Youbin Zhang, Lorenzo Gerratana, Andrew A. Davis, Huiping Liu, William J Gradishar, Carolina Reduzzi, Massimo Cristofanilli, Evi Lianidou   +12 more
wiley   +1 more source

[Assessment of patient-reported outcomes as an instrument for patient-centered care?] [PDF]

Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz
Rose M.
europepmc   +1 more source

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

Molecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata, Koji Ando, Hirofumi Hasuda, Koshi Mimori, Elizabeth C. Unan, Siddhartha Pulukuri, Aahana Tiku, Allison Berger, Eiji Oki, Ajit Bharti, Tomoharu Yoshizumi   +10 more
wiley   +1 more source

Beyond the label: patient-reported outcomes and post-approval communication in oncology. [PDF]

BMJ Oncol
Lehmann J.
europepmc   +1 more source

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

Molecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary, Jose Javier Bravo‐Cordero   +1 more
wiley   +1 more source